 |
|
Cancer cells in blood can identify risk of recurrence in breast cancer
September 25, 2007Barcelona, Spain: Cancer cells circulating in the blood, or circulating tumour cells (CTCs), are known to be associated with a bad prognosis in women with metastatic breast cancer. Now, for the first time, a group of scientists have shown that they can also detect CTCs before and after chemotherapy treatment and hence may be able to identify those patients likely to have a recurrence of their cancer after such treatment in future.
Dr. Julia Jückstock, from the University of Munich, Munich, Germany, told a press conference at the European Cancer Conference (ECCO 14) today (Monday September 24) that the results could help improve the design of trials of chemotherapy in breast cancer, as well as reducing costs to health services.
The team, led by Dr. Brigitte Rack, also from Munich, set out to look at the role of CTCs in blood at the first diagnosis of breast cancer and during adjuvant chemotherapy and endocrine treatment. They analysed blood samples from 1,767 node-positive and high-risk node-negative breast cancer patients before the start of their treatment, and compared the results to those obtained from 852 of the same patients after completion of chemotherapy.
"We found that 10 percemt of patients whose blood was sampled before the start of treatment had more than one CTC, and 5 percent of these patients had more than two CTCs in approximately 20 ml of blood," said Dr. Jückstock. The presence of CTCs did not correlate with other prognostic factors such as tumour size, grading, hormonal or Her-2 status, but the scientists did see a significant correlation with the presence of lymph node metastases.
Of 24 healthy individuals used as controls, none showed more than one CTC, said the scientists. Among the 852 patients whose blood was analysed post-treatment, 11 percent were CTC positive before the start of treatment, while 7 percent had more than one CTC after completion of chemotherapy.
Of those patients who were initially CTC positive, 10 percent remained so and 90 percent had a negative CTC test after chemotherapy. Of those initially CTC negative, 93 percent remained negative, whereas 7 percent had a positive CTC result.
The advantage of screening for CTCs is that, unlike other predictive factors, including genetic signatures, it can be carried out after the completion of primary therapy, and, if needed, on other occasions during the duration of disease. Other predictive methods can only be used on diagnosis, and only once, say the scientists.
Previous work on the detection of CTCs in bone marrow had also been shown to have predictive value, said Dr. Jückstock. "It is easier to work with bone marrow, because the volume of CTCs is much higher than in blood in the case of a positive status. However, because bone marrow is not easily accessible it is difficult to use this technique on a large scale. It is very much simpler, and more patient-friendly, to take blood samples for analysis.
"We think that the persistence of CTCs after chemotherapy treatment is likely to be predictive of the likelihood of recurrence of cancer in these patients," said Dr. Jückstock, "and we will be working to analyse the prognostic value of our findings. If this proves to be the case, it will open the door to a simple way of monitoring the likely outcome of chemotherapy, as well as enabling us to target treatments more precisely. For example, for those patients who have an increased risk of recurrence, we could prolong or alter the chemotherapy regime to give them a better chance of recovery. For those who are likely to respond well to treatment, we could reduce the length of treatment and use less aggressive therapies, thus sparing unpleasant side effects.
"We expect to have these results in the next five years," she said, "and if they are as expected, we are optimistic that our research can bring about a real improvement in the way chemotherapy is used in breast cancer patients."
Federation of European Cancer Societies
"We found that 10 percemt of patients whose blood was sampled before the start of treatment had more than one CTC, and 5 percent of these patients had more than two CTCs in approximately 20 ml of blood," said Dr. Jückstock. The presence of CTCs did not correlate with other prognostic factors such as tumour size, grading, hormonal or Her-2 status, but the scientists did see a significant correlation with the presence of lymph node metastases.
Of 24 healthy individuals used as controls, none showed more than one CTC, said the scientists. Among the 852 patients whose blood was analysed post-treatment, 11 percent were CTC positive before the start of treatment, while 7 percent had more than one CTC after completion of chemotherapy.
Of those patients who were initially CTC positive, 10 percent remained so and 90 percent had a negative CTC test after chemotherapy. Of those initially CTC negative, 93 percent remained negative, whereas 7 percent had a positive CTC result.
The advantage of screening for CTCs is that, unlike other predictive factors, including genetic signatures, it can be carried out after the completion of primary therapy, and, if needed, on other occasions during the duration of disease. Other predictive methods can only be used on diagnosis, and only once, say the scientists.
Previous work on the detection of CTCs in bone marrow had also been shown to have predictive value, said Dr. Jückstock. "It is easier to work with bone marrow, because the volume of CTCs is much higher than in blood in the case of a positive status. However, because bone marrow is not easily accessible it is difficult to use this technique on a large scale. It is very much simpler, and more patient-friendly, to take blood samples for analysis.
"We think that the persistence of CTCs after chemotherapy treatment is likely to be predictive of the likelihood of recurrence of cancer in these patients," said Dr. Jückstock, "and we will be working to analyse the prognostic value of our findings. If this proves to be the case, it will open the door to a simple way of monitoring the likely outcome of chemotherapy, as well as enabling us to target treatments more precisely. For example, for those patients who have an increased risk of recurrence, we could prolong or alter the chemotherapy regime to give them a better chance of recovery. For those who are likely to respond well to treatment, we could reduce the length of treatment and use less aggressive therapies, thus sparing unpleasant side effects.
"We expect to have these results in the next five years," she said, "and if they are as expected, we are optimistic that our research can bring about a real improvement in the way chemotherapy is used in breast cancer patients."
Federation of European Cancer Societies
Breast Cancer Current Events and Breast Cancer News RSSCarnegie Mellon researchers link health-care debate to risk of dying in US and Europe
The current health care debate in the United States is complicated. Trade-offs between heath care expenditures, lifestyle choices and life expectancy have been suggested but seldom clearly demonstrated.
Scientists uncover new key to the puzzle of hormone therapy and breast cancer
The use of postmenopausal hormone therapy has decreased over time in the United States, which researchers suggest may play a key role in the declining rate of atypical ductal hyperplasia, a known risk factor for breast cancer.
Breast density associated with increased risk of cancer recurrence
A new study finds that women treated for breast cancer are at higher risk of cancer recurrence if they have dense breasts. Published in the December 15, 2009 issue of Cancer, a peer-reviewed journal of the American Cancer Society, the study's results indicate that breast cancer patients with dense breasts may benefit from additional therapies following surgery, such as radiation.
Researcher: 'Optical biopsy' for breast cancer increasingly accurate
But women may not have to endure the medical costs, stress and potential complications that accompany such invasive biopsies forever. A University of Florida biomedical engineering researcher is making progress on an "optical biopsy" that has the potential to determine whether growths are cancerous without ever puncturing the skin.
Plastic surgeons offer microsurgery technique for breast reconstruction, tummy tuck after mastectomy
Since her teens, Jennifer Jablon had watched family members deal with breast cancer during their 40s, 50s, and 60s. She wondered whether it would be her fate too.
Experimental agent reduces breast cancer metastasis to bone
Researchers have reduced breast cancer metastasis to bone using an experimental agent to inhibit ROCK, a protein that was found to be over-expressed in metastatic breast cancer.
American Dietetic Association Releases Updated Position Paper Promoting and Supporting Breastfeeding
The American Dietetic Association has released an updated position paper on breastfeeding that details health benefits for both infants and mothers and encourages promotion of breastfeeding whenever possible.
Weight Training Boosts Breast Cancer Survivors' Body Image and Satisfaction with Intimate Relationships, Penn Study Shows
In addition to building muscle, weightlifting is also a prescription for self-esteem among breast cancer survivors, according to new University of Pennsylvania School of Medicine research.
Early-stage, HER2-positive breast cancer patients at increased risk of recurrence
Early-stage breast cancer patients with HER2 positive tumors one centimeter or smaller are at significant risk of recurrence of their disease, compared to those with early-stage disease who do not express the aggressive protein, according to a study led by researchers at The University of Texas M. D. Anderson Cancer Center.
Adapting Space-Industry Technology to Treat Breast Cancer
Researchers at Rush University Medical Center and Argonne National Laboratory are collaborating on a study to determine if an imaging technique used by NASA to inspect the space shuttle can be used to predict tissue damage often experienced by breast cancer patients undergoing radiation therapy.
More Breast Cancer Current Events and Breast Cancer News Articles
 |
New Balance Women's Lace Up X Out Breast Cancer Tech Tee (Athletic Grey, Medium) by New Balance The New Balance X Out Breast Caner Tee has a soft hand and clearly states how everyone feels! |
 |
1149 WOMENS VINTAGE BLACK ADJUSTABLE FATIGUE CAP w/PINK STRIPES & ''BREAST CANCER'' RIBBON by Rothco A portion of these proceeds go to the Babylon Breast Cancer Coalition- For Life, For Hope, For Change, For the Future Visit www.babylonbreastcancer.org for more information. |
|
|
New Balance Women's Lace Up X Out Breast Cancer Tech Tee (Athletic Grey, Small) by New Balance The New Balance X Out Breast Caner Tee has a soft hand and clearly states how everyone feels! |
 |
Breast Cancer Survival Manual, Fourth Edition: A Step-by-Step Guide for the Woman With Newly Diagnosed Breast Cancer by John Link (Author) A completely updated edition of the definitive guide for patients with breast cancer The new fourth edition of The Breast Cancer Survival Manual provides essential updates on treatment and care, enhancing the basic information that has made this the most trusted guide for women diagnosed with breast cancer for the past decade. This edition includes the most current advice on • getting a second opinion: why it’s important, what questions to ask, and how to decide which team of doctors is best for you • updates on genetic testing and how doctors are using the results to tailor care for each patient • navigating new types of radiation, the herceptin breakthrough, and improved reconstruction surgeries Conscious of the rapidly evolving spectrum of... |
 |
Breast Cancer Awareness Ribbon Promise of a Cure Cuff Bracelet by Silver Insanity This Cuff Bracelet Will Fit up to a 8" Wrist and is 3/8" Wide Crafted of a Silver Toned Base Metal and Brought to High Polish Shine Set with a Bright Pink Breast Cancer Awareness Ribbon and Inscribed With The Phrase "Promise of a Cure" |
 |
PINK RIBBON BREAST CANCER BEADED KEY CHAIN Purse Charm by MyJewelThief Beaded Pink Ribbon Breast Cancer Awareness Keychains. A mix of 4 styles! BEADS GALORE! Great for keychains, purse charms and more! Great for fund raisers! Meaures approx. 5" long! |
 |
Wrangler Women's Tough Enough To Wear Pink Breast Cancer Awareness Jacket,Pink,Medium by Wrangler Are you tough enough to wear pink? That is the question the western industry asked 12/9/05 at the Wrangler National Finals Rodeo (Wrangler NFR), the "Super Bowl of pro rodeo," as it launched Tough Enough to Wear Pink (TETWP). TETWP is a multi-year, western-industry-wide fundraiser to raise awareness and funds for breast cancer research. TETWP partners are ponying up to support this cause by manufacturing pink merchandise with proceeds benefiting breast cancer research. By wearing this Tough Enough to Wear Pink shirt you are helping in the fight against breast cancer. This TETWP shirt is a pink cotton plaid. Import. Tough Enough to Wear Pink. long sleeve zip front jacket with zippered front slash pockets and the breast cancer embroidery on left chest. 100% Polyester Fleece/100% Nylon... |
 |
Sunbeam SlumberRest Camelot Microplush Heated Throw, Breast Cancer Awareness Pink by Sunbeam Soft comfortable fabric that you can cuddle up with anywhere in your house. Use it on the couch while curling up to read a good book or in a chair while watching your favorite show. This throw is 50"x60", with a primstyle control which features 3 warming settings and 3 hour auto-off. So turn on your warming blanket, turn off your thermostat and save on your heating bill. Warm up to a good cause! Sunbeam is joining the fight against breast cancer. Through the purchase of this pink throw, sunbeam will donate $1.00 to city of hope for breast cancer research, treatment and education* up to $25,000. Program ends april 30, 2009. "to save lives and end breast cancer forever by empowering people, ensuring quality care for all, and energizing science to find the cures." *to learn more about... |
 |
Just Get Me Through This!: The Practical Guide to Breast Cancer by Deborah A. Cohen (Author), M.D., Robert M. Gelfand (Author) |
 |
Pink Ribbon BREAST CANCER Crystal Pin by MyJewelThief Genuine Austrian Crystal Layered in 18k Gold Pink Enameled Ribbon Pins. Measures approx. 1 1/2" X 1". Each individually carded. Wonderful for fund raisers! |
| © 2009 BrightSurf.com |